Symphogen A/S, a private biopharmaceutical company developing recombinant antibody mixtures, a class of antibody therapeutics under investigation for the treatment diseases such as cancer or infectious and autoimmune diseases, today announced that the company is scheduled to present next Monday, 7 January at 8 am PT in the Elizabethan C/D Ballroom of the Westin St. Francis Hotel at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
